HAGER BIOSCIENCES, LLC
Small molecule Kv1.3 channel blockers for Alzheimer's disease neuroinflammation
- Sector
- Biotech
- Total capital
- $867K
- Federal grants
- $725K
- 2 awards · 2015–2024
- Rank in peer group#92 of 502
- Private capital raised
- None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
- Federal contracts
- $142K
- 1 award · Defense
- Rank in Biotech#313 of 4373
- Granted patents
- 3
- 12 pending · first 2025
- Rank in peer group#28 of 502
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase I · Optimization of Novel Potassium Channel Kv1.3 Blockers with Potential as Alzheimer's Disease Therapeutics$500K
- Federal contractDefense · Experimental Therapeutics Medicinal Chem$142K
- Federal grantHealth and Human S · Phase I · Multi-targeted Ligands to Treat Chronic Neuropathic Pain$225K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 502 peers
Line = medianBiotech · Molecule
- Federal grants#92 · top 18%
- Granted patents#28 · top 6%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
No founders are linked to this company yet.
Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.
Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026
Claim this profile to add your teamWhat it has protected
USPTO · 3 granted of 15- PendingPyrazole And Imidazole Derivatives As Dual Orexin And Kappa-opioid Receptors Modulators Composition, Methods For Treating Neurological And Psychiatric DisordersUSPTOApplication 19105864
- GrantedPyrazole And Imidazole Derivatives, Compositions And Methods As Orexin AntagonistsUSPTOUS 12,275,744
- GrantedImidazolo Derivatives, Compositions And Methods As Orexin AntagonistsUSPTOUS 12,187,737
Show all 15 patent records
- Pyrazole And Imidazole Derivatives As Dual Orexin And Kappa-opioid Receptors Modulators Composition, Methods For Treating Neurological And Psychiatric DisordersMar 12, 2026 · Application 19105864Pending
- Pyrazole And Imidazole Derivatives, Compositions And Methods As Orexin AntagonistsApr 15, 2025 · US 12,275,744Granted
- Imidazolo Derivatives, Compositions And Methods As Orexin AntagonistsJan 7, 2025 · US 12,187,737Granted
- Imidazolo Derivatives, Compositions And Methods As Orexin AntagonistsJan 7, 2025 · US 12,187,738Granted
- Pyrazole And Imidazole Derivatives, Compositions And Methods As Orexin AntagonistsOct 6, 2022 · Application 17616142Pending
- Pyrazole And Imidazole Derivatives As Dual Orexin & Kappa-opioid Receptors Modulators, Composition, Methods For Treating Neurological And Psychiatric DisordersApplication 63403019Pending
- Substituted Pyrazoles And Imidazoles As Orexin Receptor AntagonistsApplication 63400894Pending
- Imidazole Derivatives, Compositions And Methods As Orexin AntagonistsApplication PCTUS2020035848Pending
- Pyrazole And Imidazole Derivatives, Compositions And Methods As Orexin AntagonistsApplication PCTUS2020035851Pending
- Pyrazole And Imidazole Derivatives As Dual Orexin And Kappa-opioid Receptors Modulators, Compositions, And Methods For Treating Neurological And Psychiatric DisordersApplication PCTUS2025018340Pending
- Pyrazole And Imidazole Derivatives, Compositions And Methods As Orexin AntagonistsApplication 62856822Pending
- Substituted Pyrazoles And Imidazoles As Orexin Receptor Antagonists Composition, Methods For Treating Neurological And Psychological DisordersApplication 19104451Pending
- Pyrazole And Imidazole Derivatives As Dual Orexin & Kappa-opioid Receptors Modulators, Composition, Methods For Treating Neurological And Psychiatric DisordersApplication 63561476Pending
- Pyrazole And Imidazole Derivatives As Dual Orexin And Kappa-opioid Receptors Modulators, Composition, Methods For Treating Neurological And Psychiatric DisordersApplication PCTUS2023031782Pending
- Substituted Pyrazoles And Imidazoles As Orexin Receptor Antagonists Composition, Methods For Treating Neurological And Psychiatric DisordersApplication PCTUS2023031132Pending
Related companies, and why
- PROTEIN METRICS INCSimilar federal contract value in Biotech · $147K in contracts
- DRVISION TECHNOLOGIES LLCSimilar federal contract value in Biotech · $144K in contracts
- 28bio, Inc.Similar federal contract value in Biotech · $143K in contracts
- INSMED INCSimilar federal contract value in Biotech · $139K in contracts
- ATLASXOMICS INCSimilar federal contract value in Biotech · $137K in contracts
- SIMULATIONS PLUS, INC.Similar federal contract value in Biotech · $136K in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .